Liz was appointed Country President, AstraZeneca Australia and New Zealand in October 2017. She has more than 20 years of experience in the pharmaceutical industry and has held various senior roles in sales, marketing, market access, corporate affairs and strategic planning.
Liz joined AstraZeneca Australia in a marketing role in 2003 and soon after, Liz was promoted to Market Access and Strategic Planning Director. During her time in the role, Liz established a best practice approach to market access and earned an RVP and ISMO global award in 2005. Liz was an active member of Medicines Australia Strategic Committee during the PBS reform period.
In 2008, Liz was appointed Global Head of Pricing and Market Access, AstraZeneca and was based in London. During her time in the role, Liz successfully delivered a global pricing and reimbursement strategy for new brands and supported early launch markets to achieve reimbursement goals. Liz worked closely with R&D to establish a payer evidence approach to developing brands and drove the Payer Excellence (PEX) program that improved payer capabilities across AstraZeneca. She was also involved in the PBS reform strategic committee in 2008.
Liz was appointed Vice President, Oncology, CNS and Broad Market, AstraZeneca China in 2011. In this role, she led a number of oncology brands as well as the expansion of patient access for Iressa. In 2013, Liz was appointed Country President, AstraZeneca Korea, where she led the successful launch of new products such as Forxiga, Xigduo XR, Symbicort Rapihaler, Lynparza and the fastest ever approval for Tagrisso. Liz championed operational execution through creating strong cross-functional teams, and improved commercial and medical capabilities. Her active involvement in the Korean research-based Pharmaceutical Industry Association delivered the first ever Korean Cancer Care Alliance, an alliance between academia, industry and patient groups focused on improving access to cancer.
Liz has been a member of the Medicines Australia Board since September 2018, and in March 2020 Liz was voted Deputy Chair by the MA Board.